Lighthouse Investment Partners LLC Buys Shares of 72,857 Grifols, S.A. (NASDAQ:GRFS)

Lighthouse Investment Partners LLC bought a new stake in Grifols, S.A. (NASDAQ:GRFSFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 72,857 shares of the biotechnology company’s stock, valued at approximately $842,000.

A number of other hedge funds also recently modified their holdings of GRFS. Jump Financial LLC acquired a new position in shares of Grifols during the third quarter worth $136,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 350.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 10,979 shares during the period. Morningstar Investment Services LLC acquired a new position in shares of Grifols during the fourth quarter worth $186,000. QRG Capital Management Inc. acquired a new position in shares of Grifols during the third quarter worth $303,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Grifols during the fourth quarter worth $398,000.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft lowered shares of Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

Check Out Our Latest Stock Analysis on Grifols

Grifols Trading Down 1.8 %

Shares of NASDAQ GRFS opened at $7.11 on Tuesday. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15. The firm has a fifty day simple moving average of $6.96 and a 200 day simple moving average of $7.98. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.79 and a quick ratio of 1.29.

About Grifols

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Recommended Stories

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFSFree Report).

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.